Actively Recruiting

Age: 18Years - 120Years
All Genders
NCT06362343

The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics

Led by Peking Union Medical College Hospital · Updated on 2024-04-12

300

Participants Needed

1

Research Sites

160 weeks

Total Duration

On this page

Sponsors

P

Peking Union Medical College Hospital

Lead Sponsor

R

Ruijin Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

1. Integrate pharmacokinetic-pharmacodynamic (PK-PD) modeling and pharmacogenomics techniques to develop a population PK-PD model, aiming to explore monitoring and dose guidance schemes for Direct Oral Anticoagulants (DOACs). 2. Investigate the factors influencing PK-PD of DOACs in the pulmonary embolism population, clarifying the correlation between genotype characteristics and clinical outcomes. 3. Explore the correlation between drug concentrations, coagulation indices, and clinical outcomes of DOACs, defining the indications for DOACs testing and the overall monitoring process.

CONDITIONS

Official Title

The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics

Who Can Participate

Age: 18Years - 120Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients with acute symptomatic pulmonary embolism confirmed by imaging who have completed anticoagulation for the acute phase and entered the maintenance phase
  • Expected lifespan longer than 3 months
  • Eligible for use of Xa factor inhibitors
  • Agree to participate, sign informed consent, and commit to regular follow-up
Not Eligible

You will not qualify if you...

  • Moderate or severe liver dysfunction (Child-Pugh grade B or C)
  • Severe renal impairment (creatinine clearance less than 15 ml/min)
  • Pregnant or breastfeeding women
  • Spontaneous bleeding tendency such as coagulopathy or thrombocytopenia (platelet count less than 20 x 10^9/L)
  • Contraindications to other Xa factor inhibitors
  • Diagnosed with hereditary thrombophilia or antiphospholipid syndrome

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100730

Actively Recruiting

Loading map...

Research Team

J

juhong Shi, M.D

CONTACT

Y

yiyao Li, M.D

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here